Patel Jeegar Pravinkumar 4

What Happened
Jeegar Pravinkumar Patel, Chief Scientific Officer of Evommune, was granted a derivative award of 69,315 shares on 2026-04-16. The filing lists the grant price as $0.00 and treats the award as a derivative (an option award per the footnote), so no cash was exchanged at grant.

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-17 (timely filing).
• Transaction type/code: A — Grant/award (derivative).
• Shares/units: 69,315 shares; price shown: $0.00.
• Vesting: One‑fourth vests on the first anniversary of the grant, then the remainder vests in 36 equal monthly installments thereafter (continuous service required).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Filing identifies this as an option award with the vesting schedule described above.

Context
This is a compensation-related derivative grant rather than an open‑market purchase or sale. Such awards are common for executives and are designed to align long‑term incentives; they do not by themselves indicate the insider bought or sold stock for investment purposes. The award will convert to exercisable/vested equity over time per the vesting schedule.